Olema Pharmaceuticals, Inc.
$10.51
-1.7%Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -5.6).
Valuation inputs: P/E -5.6, earnings yield N/A, momentum -1.7%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -34.0%, ROIC -37.0%).
Profitability stack: net margin 0.0%, ROE -34.0%, ROIC -37.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +10.3%, momentum -1.7%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Olema Pharmaceuticals, Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Olema Pharmaceuticals, Inc. Fair Value Envelope
No Revenue Data
OLMA has not reported any revenue values in the available annual periods.
Olema Pharmaceuticals, Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
OLMA has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
OLMA has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
OLMA has not reported any net profit margin values in the available annual periods.
Olema Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Olema Pharmaceuticals, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Olema Pharmaceuticals, Inc. Street Expectations Map
Wall Street analysts project that OLMA stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 41.88, with estimates ranging from a low of 35.00 to a high of 48.00.
The consensus 1-year price target stands at 41.88, with estimates ranging from a low of 35.00 to a high of 48.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
Good consensus alignment. Moderate target spread reflects general agreement on value drivers with some variance in assumptions.
Analyst Conviction
Positive outlook with reasonable agreement. Analysts generally optimistic about prospects with manageable uncertainty.
Market Sentiment Insight
Monitor and evaluate: Current analyst consensus suggests limited conviction or near-term catalysts. Stay informed on company developments and reassess positioning as new information emerges.
Olema Pharmaceuticals, Inc. Insider Positioning
During the last 12 months, insiders have sold $7.21M worth of OLMA shares, with no buying activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
254.7K
7.04M
-7.0M
-$7.04M
6-9 Months
0
0.00
20.0K
163.70K
-164K
-$164K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Kovacs Shane William Charles
Officer: Ch. Operating & Financial Off.
$2.98M
Myles David C.
Officer: Ch. Discov. & Non-Clin Dev Off
$1.80M
Mitchell Shawnte
Officer: Chief Legal Officer
$946K
Clark Ian T
Director
$862K
Harmon Cyrus
Director
$616K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $7.21M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
OLMA has not reported any dividend yield values in the available annual periods.
olma Dividend History
Learning Layer
Related Guides
Build conviction on OLMA by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.